The Immunology Podcast

Ep. 112: “The Evolution of mRNA-Based Dendritic Cell Cancer Vaccines” Featuring Dr. Zwi Berneman

Aug 26, 2025
Guest
Zwi Berneman
Dr. Zwi Berneman, Emeritus Professor of Hematology at the University of Antwerp, discusses the groundbreaking world of mRNA-based dendritic cell cancer vaccines. He explores their historical evolution and the scientific advancements that enhance immune responses against cancer. Funding challenges and regulatory hurdles also take center stage as he emphasizes the need for collaboration and compliance to bring these therapies to patients. With a forward-looking perspective, Berneman envisions the future potential of naked mRNA in vaccination strategies by 2030.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Dendritic Cells Control Immune Direction

  • Dendritic cells direct immune responses and can be tuned to either stimulate or suppress T cells.
  • Use immunogenic dendritic cells for cancer and tolerogenic ones for autoimmune diseases.
ANECDOTE

Switching From DNA To mRNA Guided Trials

  • Berneman shifted from DNA to mRNA loading after Gilboa's work and found electro‑poration improved transfection efficiency.
  • They validated WT1-loaded dendritic cells with T-cell assays and moved into patient trials for AML.
ADVICE

Secure Institutional Commitment And Funding

  • Build institutional commitment, retain skilled staff, and secure persistent funding before launching GMP cell therapy programs.
  • Write strong grants and partner with charities or hospital foundations to sustain production and trials.
Get the Snipd Podcast app to discover more snips from this episode
Get the app